Press ESC to close

Peptide Lab App Log in Articles News Guide Products
More Peptide Tracker Calculator Best Calculators Peptide Statistics Contact Newsletter
Français English Deutsch Español Português العربية Italiano Polski 한국어 日本語 中文 Русский Nederlands Čeština Svenska Türkçe
Clinical trial Global

Phase 3 AMPLIFY-2 will compare the EloraTZP coformulation with tirzepatide alone

Eli Lilly and Company registered AMPLIFY-2, a Phase 3 study of the eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide in adults with obesity or overweight and type 2 diabetes, in a ClinicalTrials.gov record first submitted on 12 October 2026 and first posted on 19 October 2026.

Neutral laboratory scene with sealed glass vials and a clinical research notebook on a bench

What is Tirzepatide?

Tirzepatide is a 39-amino-acid peptide built on the GIP sequence that activates both the GIP and GLP-1 receptors; a C20 fatty diacid attached to lysine 20 binds albumin and gives a half-life of about five days.

Read the full guide →

In 30 seconds

  • Eli Lilly and Company, an industry sponsor, registered AMPLIFY-2 (NCT07881458), a Phase 3 study of the coformulation EloraTZP (other name LY900043).
  • The comparator is tirzepatide (other name LY3298176) itself: both arms are labelled experimental and both are given subcutaneously, in adults with obesity or overweight and type 2 diabetes.
  • The status is not yet recruiting, with an estimated enrollment of 1000 participants and the main outcome measures set at week 100.

Why it matters

In AMPLIFY-2 the control arm is tirzepatide itself, not a placebo: the record lists two arms, EloraTZP and tirzepatide, and no placebo group. The stated purpose is to investigate the efficacy and safety of the eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes. The population is narrower than obesity alone, because every participant must have type 2 diabetes, and the record pairs a weight outcome with a glycaemic one: one of the listed measures is the percentage of participants who reach a composite of body weight reduction of 15% or more together with HbA1c below 6.5% at week 100.

The details

  • Sponsor: Eli Lilly and Company, classified as industry. The record also carries the sponsor identifier J7C-MC-YQAB and the CTIS number 2026-527230-31-00.
  • Design: interventional, Phase 3, randomized, parallel assignment, double masking (participant and investigator), primary purpose treatment. Estimated enrollment is 1000 participants.
  • Arms: EloraTZP, described as eloralintide and tirzepatide given subcutaneously, with the other name LY900043; and tirzepatide given subcutaneously, with the other name LY3298176. Both arms are labelled experimental.
  • Conditions: obesity, overweight, and diabetes mellitus type 2.
  • Outcome measures at week 100 include percent change from baseline in body weight, change from baseline in waist circumference, change from baseline in HbA1c, change from baseline in systolic blood pressure, percent change from baseline in high-sensitivity C-reactive protein, percent change from baseline in total body fat mass, change from baseline in BMI, and change from baseline in fasting glucose. Pharmacokinetics of eloralintide and of tirzepatide at steady state are followed from baseline through week 100.
  • Patient-reported measures listed at week 100 include the IWQOL-Lite CT total score, the EQ-5D-5L score, the Eating Behaviors and Attitudes Questionnaire score, a categorical shift in the Patient Global Impression of Severity for physical function weight, and the FACT-GP5 item.
  • Eligibility: adults aged 18 years and over, all sexes, no healthy volunteers. Participants must have type 2 diabetes, a BMI of 27 kg/m2 or more at screening, a stable self-reported body weight (less than 5% change) for 90 days prior to screening, and a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.
  • Exclusions include type 1 diabetes; within 90 days prior to screening, medications with direct amylin, GLP-1 or GIP receptor activity (including compounded therapies), DPP-4 inhibitors, insulin, or medications and alternative remedies intended for weight loss; a heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for congestive heart failure within 90 days prior to screening; and a history or diagnosis of New York Heart Association Class IV congestive heart failure. Prior or planned surgical, endoscopic or device-based treatment for obesity is also excluded, with the stated exceptions.
  • Oversight: the record states that a data monitoring committee is in place and that the study involves an FDA regulated drug, not an FDA regulated device.
  • Sites listed in the available record are in the United States (including Arizona, California, Colorado, Florida, Georgia, Hawaii, Indiana, Louisiana, Missouri, New Jersey, New York, Texas, Virginia and Washington), Puerto Rico, Brazil, China, Germany, Japan and Romania.

What it does not change

This is a registry entry, not a result and not an approval. No efficacy or safety data appear in the record, and the overall status is not yet recruiting, so the record describes a planned study rather than one under way. Both EloraTZP and tirzepatide are labelled experimental in this study, and the record contains no regulatory submission, decision or marketing information in any country.

What's next

The status was verified in October 2026, the record was first submitted on 12 October 2026 and first posted on 19 October 2026. The estimated dates given are November 2026, then October 2029 and November 2029, and the record states that participation in the study will last about 2 years. The next visible step would be a change of the overall status from not yet recruiting, and the first reading of the listed measures falls at week 100.

What we don't know yet

Nothing in the record indicates whether the coformulation reduces body weight more than tirzepatide alone, and no interim or exploratory figures are reported. The record does not label which of its estimated dates is the study start, the primary completion or the overall completion, and it does not set out the statistical analysis plan, the randomization ratio between the two arms, or how the many listed measures are ranked. The site list in the available record is incomplete, so the full set of participating countries is not known from this source.

Products sold online as research peptides are not the medicines studied or approved in this news. A medicine is available in a country only after that country's medicines agency approves it.

Source documents

This article reports news for information only. It is not medical or legal advice and does not recommend any use or dose. Every fact comes from the source documents listed above.